The effects of the local acting antibiotic Rifaximin on markers of inflammation in the blood by changing the bacterial composition in the gut, in patients with common variable immunodeficiency.

Conditions: Adult patients with the diagnosis of Common variable deficiency and fulfill the inclusion and exclusion criteria, will be invited to participate in the study.
Therapeutic area: Diseases [C] - Immune System Diseases [C20]

Registration Number: EUCTR2013-000883-27-NO

Lead Sponsor: Oslo University hospital

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Authorised-recruitment may be ongoing or finished

Sex: All

Target Recruitment: Not specified

Inclusion Criteria

The patients will be recruited from the Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet.
All of the following conditions must apply to the prospective patient at screening prior to receiving study agent:
•A diagnosis of CVID based on ESID guidelines
•18 = and <75 years of age

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 50
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 6

Exclusion Criteria

•Previous treatment with antibiotics within the last 12 weeks
•History of hypersensitivity to Rifaximin or other rifamycin derived antimicrobial agents, or any of the components of XIFAXAN
•Comorbidity not related to CVID (e.g., cardiovascular disorders].
•Polypharmica with increased risk for interactions.
•Malignancy of any cause
•Impaired kidney function (i.e., estimated glomerulus filtration rate <50 ml/minute/1.73 m2]
•Alanine aminotransferase > 150 U/l or established liver cirrhoses.
•Pregnant or planning to be pregnant in the study period to avoid interference of pregnancy with gut microbiota (not because of toxicity].
•Nursing
•On-going infection, including GI infection
•The use of probiotics for the recent 6 months
•Any immunosuppressive drugs